Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

POLD1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

POLD1 mutation	Gastric Cancer	POLD1 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
POLD1 mutation	Gastric Cancer	POLD1 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
POLD1 mutation	Solid Tumor	POLD1 mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLD1 mutation	Solid Tumor	POLD1 mutation	Solid Tumor	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
POLD1 mutation	Non Small Cell Lung Cancer	POLD1 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
POLD1 mutation	Gastroesophageal Cancer	POLD1 mutation	Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3